Concluding Remarks
Hyperkalemia is a common electrolyte abnormality after KT with an
incidence ranging from 25-44% in KT recipients on CNIs.[2] In KT
patients, factors such as tubular dysfunction and various drug classes
may increase the risk of hyperkalemia. Limited data exist in the kidney
transplant population on the management of hyperkalemia. Our
recommendations are mainly based on data from studies in patients with
CKD. Nevertheless, KT patients by definition have CKD and the approach
to treating hyperkalemia should be generally the same. Understanding the
pathophysiology, treatment options, as well as limitations are all key
to the successful treatment and prevention of hyperkalemia post-kidney
transplant.